New drugs for asthma
- 1 October 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 3 (10) , 831-844
Abstract
Asthma is a major and increasing global health problem and, despite major advances in therapy, many patients' symptoms are not adequately controlled. Treatment with combination inhalers, which contain a corticosteroid and long-acting β2 adrenoceptor agonist, is the most effective current therapy. There is therefore a search for new therapies, particularly safe and effective oral treatments and those that are more efficacious in severe asthma. New therapies in development include mediator antagonists and inhibitors of cytokines, although these therapies might be too specific to be very effective. New anti-inflammatory therapies include corticosteroids and inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinase and nuclear factor-κB. The prospects for a curative treatment are on the horizon.Keywords
This publication has 161 references indexed in Scilit:
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trialAnnals of Allergy, Asthma & Immunology, 2002
- Cyclic nucleotide phosphodiesterasesJournal of Allergy and Clinical Immunology, 2001
- Protease-activated receptors in human airways: Upregulation of PAR-2 in respiratory epithelium from patients with asthmaJournal of Allergy and Clinical Immunology, 2001
- Effects of purine and pyrimidine nucleotides on intracellular Ca2+ in human eosinophils: Activation of purinergic P2Y receptorsJournal of Allergy and Clinical Immunology, 2001
- Biologic activities of IL-1 and its role in human diseaseJournal of Allergy and Clinical Immunology, 1998
- Src family‐selective tyrosine kinase inhibitor, PP1, inhibits both FcεRI‐ and Thy‐1‐mediated activation of rat basophilic leukemia cellsEuropean Journal of Immunology, 1997
- Chloride transport and the action of sodium cromoglycate and nedocromil sodium in asthmaClinical & Experimental Allergy, 1996
- The potential role of tumour necrosis factor a in asthmaClinical & Experimental Allergy, 1993